US EditionSecarna Pharmaceuticals and Curie.Bio portfolio company enter research and option agreement - Pharmafile
Summary by pharmafile.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Secarna Pharmaceuticals and Curie.Bio portfolio company enter research and option agreement - Pharmafile
Global biopharma company, Secarna Pharmaceuticals, and biotech investor, Cure.Bio, have announced signing a research and option agreement, intending to accelerate the development of Secarna’s oligonucleotide therapeutics. Under the agreement, Secarna will leverage its OligoCreator platform in exchange for a technology access fee, research funding and warrants to purchase shares in Cure.Bio upon the achievement of […] The post Secarna Pharmaceuti…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
